HUB Investment Partners LLC Trims Stock Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• HUB Investment Partners cut its stake in IDEXX by 11.8% in Q3 to 34,835 shares (about $22.26M), while institutional investors own roughly 87.8% of the stock.
• IDEXX slightly missed EPS at $2.92 versus a $2.93 estimate but beat revenue at $1.09B, posted 14.3% year‑over‑year revenue growth and issued FY 2026 EPS guidance of 14.29–14.80.
• Company insiders have sold 45,957 shares (~$29.86M) in the past 90 days (insiders now own 0.98%), and analysts hold a consensus "Moderate Buy" rating with an average target of $783.33.

HUB Investment Partners LLC cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,835 shares of the company's stock after selling 4,639 shares during the period. IDEXX Laboratories comprises approximately 0.7% of HUB Investment Partners LLC's investment portfolio, making the stock its 23rd biggest holding. HUB Investment Partners LLC's holdings in IDEXX Laboratories were worth $22,256,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in IDXX. Blalock Williams LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $590,000. New York State Common Retirement Fund increased its holdings in shares of IDEXX Laboratories by 6.8% during the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company's stock valued at $38,477,000 after purchasing an additional 3,820 shares in the last quarter. Mediolanum International Funds Ltd lifted its stake in shares of IDEXX Laboratories by 14.5% in the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company's stock valued at $24,441,000 after purchasing an additional 4,909 shares during the period. Principal Financial Group Inc. boosted its holdings in IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company's stock worth $840,638,000 after buying an additional 187,967 shares in the last quarter. Finally, Orion Porfolio Solutions LLC grew its position in IDEXX Laboratories by 116.6% during the second quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company's stock valued at $5,749,000 after buying an additional 5,770 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $608.41 on Friday. The firm has a 50-day simple moving average of $666.94 and a 200-day simple moving average of $668.20. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $48.44 billion, a price-to-earnings ratio of 46.55, a price-to-earnings-growth ratio of 3.76 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The business had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm's revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the business's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares of the company's stock, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the company's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company's stock, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on IDXX shares. Piper Sandler lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research note on Monday, February 9th. Barclays reduced their price target on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Wall Street Zen lowered IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 28th. BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Finally, UBS Group decreased their target price on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.